News and Press Releases
Emerson Introduces Next-Generation Industrial Data Fabric, Providing Foundation for Highly Integrated Industrial Data Platform
Enhanced AspenTech Inmation OT Data Fabric to accelerate enterprise-scale intelligence 13 May 2026 -- Texas, US -- Global automation leader Emerson today announced major advancements to the AspenTech Inmation™ OT...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 13, 2026
Neurizon Receives Ethics Approval for Phase 1 NUZ-001 Oral Liquid Formulation Study
Bellberry Human Research Ethics Committee (HREC) approves Neurizon’s Phase 1 formulation study supporting development of the NUZ-001 oral liquid formulation and continued advancement of NUZ-001 for amyotrophic lateral sclerosis (ALS)...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2026
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF) Findings...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
AOP Health and VRG Therapeutics Enter Co-Development Partnership for New Immunology Program
12 May 2026 -- Vienna, Austria and Budapest, Hungary -- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
Vibra to Support Expansion of MindMaze Therapeutics’ Neurorehabilitation Platform across Leading U.S. Health Systems 12 May 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
New Emerson Industrial AI Platform Delivers Enterprise-Scale AI
AspenTech AVA enables customers to act faster, develop more informed strategies, improve operational reliability 11 May 2026 -- Missouri, US -- Global automation leader Emerson today introduced the AspenTech AVA AI platform,...
Category: Logistics, Other
Posted: May 11, 2026
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
Collaboration targets large provider groups to accelerate adoption of MindMaze Therapeutics’ evidence-based neurotherapeutic platform 30 April 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Other, Pharmaceutical
Posted: April 30, 2026
U.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics’ mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I Disorder
29 April 2026 -- California, US -- Laguna Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s mRNA Gene...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance
Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
IMAAVY (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE)...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing
12 March 2026 -- Delaware and Massachuetts, US -- BioCurie, a TechBio company building an AI-driven digital platform for cell and gene therapy manufacturing, was awarded up to $9.3 million...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 12, 2026
Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline
Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD 17 February 2026 -- Heidelberg, Germany -- FundaMental Pharma GmbH, a preclinical-stage...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By targeting the hippocampus region of the brain, evenamide...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 3, 2026
MetP Pharma’s Neural Targeting Drug Delivery Technology Sets a New Benchmark for Brain Delivery of Peptides
Intranasal nose-to-brain delivery achieves superior brain exposure with low systemic burden, outperforming transporter-based BBB technologies in preclinical studies 29 January 2026 -- Emmetten, Switzerland -- MetP Pharma AG, a pioneer...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: January 29, 2026
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland
